SE0201863D0 - Cell penetrating peptides - Google Patents

Cell penetrating peptides

Info

Publication number
SE0201863D0
SE0201863D0 SE0201863A SE0201863A SE0201863D0 SE 0201863 D0 SE0201863 D0 SE 0201863D0 SE 0201863 A SE0201863 A SE 0201863A SE 0201863 A SE0201863 A SE 0201863A SE 0201863 D0 SE0201863 D0 SE 0201863D0
Authority
SE
Sweden
Prior art keywords
cpp
present
relates
predicting
verifying
Prior art date
Application number
SE0201863A
Other languages
Unknown language ( )
English (en)
Inventor
Margus Pooga
Madis Metsis
Priit Kogerman
Andreas Valkna
Anne Meikas
Samir El-Andaloussi
Maria Lindgren
Astrid Graeslund
Goeran Eriksson
Claes Goeran Oestensson
Metka Budihna
Matjaz Zorko
Anna Elmquist
Ursel Soomets
Pontus Lundberg
Uelo Langel
Kalle Kilk
Mattias Haellbrink
Original Assignee
Cepep Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cepep Ab filed Critical Cepep Ab
Priority to SE0201863A priority Critical patent/SE0201863D0/
Publication of SE0201863D0 publication Critical patent/SE0201863D0/
Priority to JP2004513322A priority patent/JP4503435B2/ja
Priority to EP03760107A priority patent/EP1516184B1/en
Priority to PCT/IB2003/003163 priority patent/WO2003106491A2/en
Priority to HK05108432.4A priority patent/HK1078130B/en
Priority to US10/517,079 priority patent/US20080234183A1/en
Priority to AT03760107T priority patent/ATE368853T1/de
Priority to DE60315296T priority patent/DE60315296T2/de
Priority to AU2003253125A priority patent/AU2003253125A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K51/0448—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil tropane or nortropane groups, e.g. cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Optics & Photonics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
SE0201863A 2002-06-18 2002-06-18 Cell penetrating peptides SE0201863D0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
SE0201863A SE0201863D0 (en) 2002-06-18 2002-06-18 Cell penetrating peptides
JP2004513322A JP4503435B2 (ja) 2002-06-18 2003-06-18 細胞選択的送達系
EP03760107A EP1516184B1 (en) 2002-06-18 2003-06-18 Cell-selective delivery system
PCT/IB2003/003163 WO2003106491A2 (en) 2002-06-18 2003-06-18 Cell penetrating peptides
HK05108432.4A HK1078130B (en) 2002-06-18 2003-06-18 Cell-selective delivery system
US10/517,079 US20080234183A1 (en) 2002-06-18 2003-06-18 Cell Penetrating Peptides
AT03760107T ATE368853T1 (de) 2002-06-18 2003-06-18 Zell-selektives abgabe system
DE60315296T DE60315296T2 (de) 2002-06-18 2003-06-18 Zell-selektives Abgabe System
AU2003253125A AU2003253125A1 (en) 2002-06-18 2003-06-18 Cell penetrating peptides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0201863A SE0201863D0 (en) 2002-06-18 2002-06-18 Cell penetrating peptides
US39178802P 2002-06-25 2002-06-25

Publications (1)

Publication Number Publication Date
SE0201863D0 true SE0201863D0 (en) 2002-06-18

Family

ID=29738564

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0201863A SE0201863D0 (en) 2002-06-18 2002-06-18 Cell penetrating peptides

Country Status (8)

Country Link
US (1) US20080234183A1 (enExample)
EP (1) EP1516184B1 (enExample)
JP (1) JP4503435B2 (enExample)
AT (1) ATE368853T1 (enExample)
AU (1) AU2003253125A1 (enExample)
DE (1) DE60315296T2 (enExample)
SE (1) SE0201863D0 (enExample)
WO (1) WO2003106491A2 (enExample)

Families Citing this family (191)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
US8003595B2 (en) 2000-03-01 2011-08-23 Cellectis Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei
US7696168B2 (en) 2000-04-21 2010-04-13 Tufts Medical Center, Inc. G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same
CA2406839C (en) * 2000-04-21 2013-06-11 Athan Kuliopulos G-protein coupled receptor (gpcr) agonists and antagonists and methods of activating and inhibiting gpcr using the same
GB0313132D0 (en) * 2003-06-06 2003-07-09 Ich Productions Ltd Peptide ligands
EP1653989B1 (fr) 2003-08-14 2009-07-15 Diatos Composition anti-bacterienne plus particulierement contre les bacteries gram negatif comprenent un peptide et un agent anti-bacterien avantageusement hydrophobe
EP1512696A1 (en) * 2003-08-14 2005-03-09 Diatos Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei
DK2332968T3 (en) 2003-11-05 2016-08-22 Dana Farber Cancer Inst Inc Alpha-helix peptides suitable for activating or inhibiting cell death
CA2565685A1 (en) * 2004-05-04 2005-12-15 Nastech Pharmaceutical Company Inc. Compositions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
US20060040882A1 (en) 2004-05-04 2006-02-23 Lishan Chen Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
CN101072566B (zh) * 2004-11-03 2012-05-16 为人技术株式会社 用于经皮给药的药物组合物
EP2380904A1 (en) * 2004-11-04 2011-10-26 Tufts Medical Center, Inc. G protein coupled receptor agonists and antagonists and methods of use
FR2877946B1 (fr) 2004-11-12 2011-02-11 Commissariat Energie Atomique Peptides derives de la maurocalcine utilisables comme vecteurs pour l'adressage intracellulaire de molecules d'interet
JP2008525005A (ja) 2004-12-22 2008-07-17 リポペプチド・アクチエボラーグ 新規の物質、および、それらの使用
EP1846014B1 (en) * 2005-01-18 2012-10-24 The Board of Governors for Higher Education State of Rhode Island and Providence Plantations Selective delivery of molecules into cells or marking of cells in diseased tissue regions using environmentally sensitive transmembrane peptide
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
RU2507213C2 (ru) 2005-10-04 2014-02-20 Солидженикс, Инк., Новые пептиды для лечения и профилактики иммунопатологических заболеваний, включая лечение и профилактику инфекции посредством модулирования врожденного иммунитета
US8299214B2 (en) * 2006-03-13 2012-10-30 Keio University Influenza infection-inhibiting peptide, influenza virus infection inhibitor, liposome, and influenza preventive/therapeutic agent
WO2008063315A2 (en) * 2006-10-13 2008-05-29 University Of Southern California C-TERMINAL DOMAIN TRUNCATION OF MGLUR1α BY CALPAIN AND USES THEREOF
EP2980219B1 (en) 2006-12-28 2018-11-14 International Institute of Cancer Immunology, Inc. Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
JP5518488B2 (ja) * 2007-01-29 2014-06-11 プロセル セラピューティックス インコーポレーティッド 巨大分子伝達ドメインならびにその同定方法および使用
PL2118123T3 (pl) 2007-01-31 2016-06-30 Dana Farber Cancer Inst Inc Stabilizowane peptydy p53 i ich zastosowania
DE102007008596B4 (de) * 2007-02-15 2010-09-02 Friedrich-Schiller-Universität Jena Biologisch wirksame Moleküle auf Grundlage von PNA und siRNA, Verfahren zu deren zellspezifischen Aktivierung sowie Applikationskit zur Verabreichung
KR101525754B1 (ko) 2007-03-28 2015-06-09 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스티칭된 폴리펩티드
US9078927B2 (en) * 2007-07-06 2015-07-14 Cedars-Sinai Medical Center Self-assembling complex for targeting chemical agents to cells
WO2009032148A1 (en) 2007-08-29 2009-03-12 Tufts University Methods of making and using a cell penetrating peptide for enhanced delivery of nucleic acids, proteins, drugs, and adenovirus to tissues and cells, and compositions and kits
WO2009041902A1 (en) * 2007-09-25 2009-04-02 Loefgren Kajsa Prion protein derived cell penetrating peptides and their uses
TW200932260A (en) * 2007-11-28 2009-08-01 Oncotherapy Science Inc STAT3 epitope peptides
CN104474529A (zh) 2008-02-08 2015-04-01 爱勒让治疗公司 治疗性的拟肽大环化合物
EP2090584A1 (en) 2008-02-13 2009-08-19 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Identification of a novel cysteine-rich cell penetrating peptide
DE102009043743B4 (de) 2009-03-13 2016-10-13 Friedrich-Schiller-Universität Jena Zellspezifisch wirksame Moleküle auf Grundlage von siRNA sowie Applikationskits zu deren Herstellung und Verwendung
CA2713872A1 (en) * 2008-02-21 2009-08-27 Burnham Institute For Medical Research Methods and compositions related to peptides and proteins with c-terminal elements
GB0804496D0 (en) 2008-03-11 2008-04-16 Theryte Ltd Treating cancer
US20110195911A1 (en) * 2008-03-28 2011-08-11 The United States Of America,As Represented By The Secretary,Department Of Health & Human Services Synthetic analogs of the juxtamembrane domain of igf1r and uses thereof
CA2723192A1 (en) * 2008-05-07 2009-11-12 Surmodics, Inc. Delivery of nucleic acid complexes from particles
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
US20110250685A1 (en) * 2008-06-03 2011-10-13 Nash Huw M Compositions and methods for enhancing cellular transport of biomolecules
US8575305B2 (en) 2008-06-04 2013-11-05 Medical Research Council Cell penetrating peptides
US8420775B2 (en) 2008-06-12 2013-04-16 Centre For Addiction And Mental Health Polypeptides and methods for modulating D1-D2 dopamine receptor interaction and function
US20110218334A1 (en) * 2008-07-11 2011-09-08 Alnylam Pharmaceuticals, Inc. PHOSPHOROTHIOATE OLIGONUCLEOTIDES AND NON-NUCLEOSIDIC PHOSPHOROTHIOATES AS DELIVERY AGENTS FOR iRNA AGENTS
WO2010011313A2 (en) 2008-07-23 2010-01-28 President And Fellows Of Harvard College Ligation of stapled polypeptides
CN102203126A (zh) 2008-09-22 2011-09-28 爱勒让治疗公司 用于制备纯化的多肽组合物的方法
US20140248296A1 (en) * 2008-10-16 2014-09-04 Kathleen Cogan Farinas Sustained drug delivery system
WO2010053548A2 (en) * 2008-11-04 2010-05-14 Anchor Therapeutics, Inc. Pthr1 receptor compounds
WO2010053547A2 (en) * 2008-11-04 2010-05-14 Anchor Therapeutics, Inc. Cxcr5 receptor compounds
WO2010072228A1 (en) * 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
EP2641911A3 (en) * 2008-12-23 2014-01-01 Vivoscript, Inc. Compositions and methods for re-programming cells without genetic modification
EP2376100B1 (en) 2009-01-14 2017-10-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2010085665A2 (en) * 2009-01-23 2010-07-29 Cedars-Sinai Medical Center Targeted delivery system
SI2417156T1 (sl) 2009-04-07 2015-06-30 Roche Glycart Ag Trivalentna, bispecifiäśna protitelesa
EP2417154A4 (en) 2009-04-09 2013-03-13 Ct For Addiction And Mental Health DOPAMINE D2 RECEPTOR DISC1 INTERACTION AND COMPOSITIONS AND METHOD FOR MODULATING THEREOF
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
GB0910620D0 (en) 2009-06-19 2009-08-05 Immunovia Ab Agents and uses thereof
BRPI1015424B1 (pt) 2009-06-22 2022-01-18 Burnham Institute For Medical Research Composição compreendendo um elemento cendr e uma co-composição e composição para uso no reforço da internalização, penetração, ou ambas, de uma co-composição
WO2011008260A2 (en) 2009-07-13 2011-01-20 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
CN102712675A (zh) 2009-09-22 2012-10-03 爱勒让治疗公司 拟肽大环化合物
US9808504B2 (en) * 2009-09-22 2017-11-07 Yale University Immunogenic epitopes as targets for universal cancer vaccines
CA2780741C (en) 2009-10-12 2023-04-04 Smith Holdings, Llc Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
WO2011072292A2 (en) * 2009-12-11 2011-06-16 Dicerna Pharmaceuticals, Inc. Phase changing formulations of rna and rna derivatives
US20110159098A1 (en) * 2009-12-30 2011-06-30 Surmodics, Inc. Stabilization and delivery of nucleic acid complexes
AU2011248625B2 (en) 2010-04-26 2017-01-05 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase
WO2011139799A2 (en) 2010-04-27 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases
EP2563911B1 (en) 2010-04-28 2021-07-21 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases
AU2011248490B2 (en) 2010-04-29 2016-11-10 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases
JP5991963B2 (ja) 2010-04-29 2016-09-14 エータイアー ファーマ， インコーポレイテッド バリルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
AU2011248355B2 (en) 2010-05-03 2017-01-19 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Arginyl-tRNA synthetases
WO2011140132A2 (en) 2010-05-03 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases
JP6008841B2 (ja) 2010-05-03 2016-10-19 エータイアー ファーマ， インコーポレイテッド メチオニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
WO2011140267A2 (en) 2010-05-04 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex
CA2799197C (en) 2010-05-14 2019-10-29 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
JP6046607B2 (ja) 2010-05-27 2016-12-21 エータイアー ファーマ， インコーポレイテッド グルタミニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
AU2011261486B2 (en) 2010-06-01 2017-02-23 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-tRNA synthetases
US9540680B2 (en) * 2010-06-07 2017-01-10 The Trustees Of The University Of Pennsylvania Transcriptome in vivo analysis
RU2556800C2 (ru) 2010-06-14 2015-07-20 Ф.Хоффманн-Ля Рош Аг Пептиды, проникающие в клетки, и их применения
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
EP2585592A4 (en) * 2010-06-23 2013-08-21 Vivoscript Inc COMPOSITIONS AND METHODS FOR RENEWING CELLS WITHOUT GENETIC MODIFICATION FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
AU2011289831C1 (en) 2010-07-12 2017-06-15 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
WO2012021144A1 (en) 2010-08-12 2012-02-16 New York University Oligooxopiperazines and methods of making and using them
CA2807685C (en) 2010-08-13 2020-10-06 Aileron Therapeutics, Inc. P53 derived peptidomimetic macrocycle
CN103068846B9 (zh) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
JP5753903B2 (ja) * 2010-08-24 2015-07-22 ロシュ グリクアート アーゲー 活性化可能な二重特異性抗体
CA2808539C (en) 2010-08-25 2021-05-25 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tyrosyl-trna synthetases
WO2012040459A2 (en) 2010-09-22 2012-03-29 President And Fellows Of Harvard College Beta-catenin targeting peptides and uses thereof
JP5857056B2 (ja) 2010-10-14 2016-02-10 ザイジェン インフラメーション エルティーディー 慢性又は非慢性の炎症性眼疾患を治療するためのｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤の使用
US9518105B2 (en) * 2010-12-08 2016-12-13 The Research Foundation For The State University Of New York Polypeptides derived from calcitonin receptors and methods of use
WO2012090150A2 (en) 2010-12-27 2012-07-05 Compugen Ltd New cell-penetrating peptides and uses thereof
US8901092B2 (en) 2010-12-29 2014-12-02 Surmodics, Inc. Functionalized polysaccharides for active agent delivery
BR112013020338A2 (pt) 2011-02-28 2016-10-18 Hoffmann La Roche proteína de ligação de antígeno monovalente, composição farmacêutica, uso da proteína de ligação de antígeno monovalente, método para o tratamento de um paciente com necessidade de terapia, método para a preparação de uma proteína de ligação de antígeno monovalente, ácido nucleico, vetor e célula hospedeira
WO2012118778A1 (en) 2011-02-28 2012-09-07 Sanford-Burnham Medical Research Institute Truncated car peptides and methods and compositions using truncated car peptides
WO2012116926A1 (en) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Antigen binding proteins
US10913781B2 (en) 2011-04-08 2021-02-09 Tufts Medical Center, Inc. Pepducin design and use
CA2834577A1 (en) * 2011-05-23 2012-11-29 Phylogica Limited Method of determining, identifying or isolating cell-penetrating peptides
AU2012262488A1 (en) 2011-05-31 2014-01-16 Airware, Inc. Re-calibration of AB NDIR gas sensors
US9487562B2 (en) 2011-06-17 2016-11-08 President And Fellows Of Harvard College Stabilized polypeptides as regulators of RAB GTPase function
EP2537858A1 (en) 2011-06-20 2012-12-26 Commissariat à l'Énergie Atomique et aux Énergies Alternatives Small efficient cell penetrating peptides derived from the scorpion toxin maurocalcine
US10179801B2 (en) 2011-08-26 2019-01-15 Sanford-Burnham Medical Research Institute Truncated LYP-1 peptides and methods and compositions using truncated LYP-1 peptides
ES2876939T3 (es) 2011-08-30 2021-11-15 Res & Innovation Uk Péptidos penetradores de células que tienen un dominio hidrófobo central
EP2755679B1 (en) * 2011-09-13 2017-08-02 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
US9259483B2 (en) 2011-11-24 2016-02-16 Positec Power Tools (Suzhou) Co Ltd Peptide sequence design and use thereof for peptide-mediated siRNA delivery
CN102532565B (zh) * 2011-12-19 2013-08-28 上海交通大学 可降解亚胺类聚阳离子及其合成方法、纳米颗粒
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
BR112014020103A2 (pt) 2012-02-15 2018-10-09 Aileron Therapeutics, Inc. macrociclos peptidomiméticos
CA2864120A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
CN104334541A (zh) 2012-02-16 2015-02-04 纽约大学 使用低聚氧代哌嗪非肽螺旋模拟物对低氧诱导基因表达的控制
CA2869283A1 (en) * 2012-06-26 2014-01-03 F. Hoffmann-La Roche Ag Cell penetrating peptides & methods of identifying cell penetrating peptides
US10036009B2 (en) 2012-08-03 2018-07-31 Cedars-Sinai Medical Center Isolating traffic-enhancing mutants of drug delivery protein
EP2708235A1 (en) 2012-09-17 2014-03-19 Commissariat A L'energie Atomique Et Aux Energies Alternatives Peptide antagonists of the vasopressin-2 receptor
RS61957B1 (sr) 2012-09-26 2021-07-30 Harvard College Uvezani peptidi blokirani prolinom i njihove upotrebe
KR20150082307A (ko) 2012-11-01 2015-07-15 에일러론 테라퓨틱스 인코포레이티드 이치환 아미노산 및 이의 제조 및 사용 방법
EP2922869B1 (en) 2012-11-25 2017-09-27 The Regents of The University of California Peptides that stimulate subcutaneous adipogenesis
ITMI20122263A1 (it) * 2012-12-28 2014-06-29 Azienda Ospedaliero Universitaria Di Parma Nuovi peptidi cationici ciclici ad attività antimicrobica
EP3782638A1 (en) 2013-03-13 2021-02-24 President and Fellows of Harvard College Stapled and stitched polypeptides and uses thereof
EP2784094A1 (en) 2013-03-28 2014-10-01 Commissariat A L'energie Atomique Et Aux Energies Alternatives New uranium-chelating peptides derived from EF-hand calcium-binding motif useful for uranium biodetection and biodecontamination
AU2014240783B2 (en) 2013-03-28 2019-02-14 Commissariat A L'energie Atomique Et Aux Energies Alternatives New uranium-chelating peptides derived from EF-hand calcium-binding motif useful for uranium biodetection and biodecontamination
US10227390B2 (en) 2013-06-14 2019-03-12 President And Fellows Of Harvard College Stabilized polypeptide insulin receptor modulators
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
AU2014301960A1 (en) * 2013-06-26 2016-01-07 Phylogica Limited Method of monitoring cellular trafficking of peptides
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
AU2014301631A1 (en) 2013-06-26 2015-08-27 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
EP2842566A1 (en) 2013-09-03 2015-03-04 Centre National De La Recherche Scientifique Use of arpin a new inhibitor of the arp2/3 complex for the diagnosis and treatment of diseases
KR20160044060A (ko) 2013-10-11 2016-04-22 에프. 호프만-라 로슈 아게 다중특이적 도메인 교환된 통상의 가변 경쇄 항체
JP6493216B2 (ja) * 2013-11-05 2019-04-03 味の素株式会社 ペプチドヒドラジド、ペプチドアミド及びペプチドチオエステルの製造方法
WO2015097267A1 (en) * 2013-12-23 2015-07-02 Covalab mTG SUBSTRATES FOR COVALENT CONJUGATION OF COMPOUNDS
WO2015105957A1 (en) 2014-01-08 2015-07-16 Shriners Hospitals For Children Pten antagonist peptides and methods of using the same
US10682388B2 (en) * 2014-01-15 2020-06-16 The Board Of Regents Of The University Of Texas System Targeting of PELP1 in cancer therapy
MX381016B (es) 2014-01-17 2025-03-12 Cedars Sinai Medical Center Composiciones de nanopartículas para su uso en la entrega de una carga útil al cerebro.
EP2905031A1 (en) 2014-02-10 2015-08-12 B Cell Design A new non-HIV vaccine antigen from the vaginal microbiota capable of inducing a mucosal neutralizing protective antibody response against HIV infection
MX2016013025A (es) 2014-04-04 2017-04-27 Cedars Sinai Medical Center Focalizacion de cancer de mama her2+ resistente a trastuzumab con una nanoparticula dirigida de her3.
JP6759109B2 (ja) 2014-05-21 2020-09-23 プレジデント アンド フェローズ オブ ハーバード カレッジ Ｒａｓ抑制性ペプチドおよびその使用
US10844102B2 (en) 2014-05-28 2020-11-24 The Regents Of The University Of California Peptides, compositions, and methods for stimulating subcutaneous adipogenesis
SG10201902598VA (en) 2014-09-24 2019-04-29 Aileron Therapeutics Inc Peptidomimetic macrocycles and formulations thereof
MX2017003797A (es) 2014-09-24 2017-06-15 Aileron Therapeutics Inc Macrociclos peptidomimeticos y usos de los mismos.
WO2016087416A1 (en) 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Multispecific antibodies
US10253067B2 (en) 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
ES2983924T3 (es) 2015-03-27 2024-10-28 Immatics Biotechnologies Gmbh Péptidos novedosos y combinación de péptidos para usarse en inmunoterapia contra diferentes tumores
US9795624B2 (en) 2015-05-04 2017-10-24 Research Foundation Of The City University Of New York Cationic polymers as co-drugs for chemotherapeutic agents
WO2017004548A1 (en) 2015-07-01 2017-01-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CN108368161A (zh) 2015-09-10 2018-08-03 艾瑞朗医疗公司 作为mcl-1调节剂的拟肽大环化合物
AU2016354478B2 (en) 2015-11-13 2021-07-22 Oasis Pharmaceuticals, LLC Protease-activated receptor-2 modulators
US12050215B2 (en) * 2015-11-17 2024-07-30 The Regents Of The University Of Michigan Macromolecular structures and uses thereof
EP4039698A1 (en) * 2016-03-15 2022-08-10 IDP Discovery Pharma, S.L. Peptides with anti-cancer activity
GB201607521D0 (en) * 2016-04-29 2016-06-15 Oncolmmunity As Method
US10876116B2 (en) 2016-07-15 2020-12-29 The Board Of Regents Of The University Of Oklahoma Anti-ARID3a treatments for inflammatory disorders
GB201618432D0 (en) * 2016-11-01 2016-12-14 Matn Scient Ltd Detection and treatment of demyelinating diseases
EP3538125A4 (en) 2016-11-09 2020-10-07 Ohio State Innovation Foundation DISULPHIDE-BOUND CELL PENETRATION PEPTIDES, THEIR PREPARATION AND USE METHODS
US11352394B2 (en) 2016-11-22 2022-06-07 Ohio State Innovation Foundation Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof
IL302130A (en) 2016-12-07 2023-06-01 Molecular Templates Inc Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
CA3087881A1 (en) 2017-01-17 2018-07-26 Michael David FORREST Therapeutic inhibitors of the reverse mode of atp synthase
EP3360891B1 (en) 2017-02-14 2022-03-30 Karlsruher Institut für Technologie Cell penetrating peptides of human origin
WO2018204392A1 (en) 2017-05-02 2018-11-08 Stanford Burnham Prebys Medical Discovery Institute Tumor associated monocyte/macrophage binding peptide and methods of use thereof
KR102095284B1 (ko) * 2017-05-11 2020-04-01 (주)케어젠 메토트렉세이트와 펩타이드의 결합체
CA3099077A1 (en) 2017-07-13 2019-01-17 Michael David FORREST Therapeutic modulators of the reverse mode of atp synthase
US10905770B2 (en) 2017-07-17 2021-02-02 Macregen, Inc. Topical delivery of therapeutic agents using cell-penetrating peptides for the treatment of age-related macular degeneration and other eye diseases
WO2019058263A1 (en) * 2017-09-19 2019-03-28 Auckland Uniservices Limited PEPTIDES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH DYSFUNCTION OF ADIPONECTIN
WO2019070962A1 (en) 2017-10-04 2019-04-11 Ohio State Innovation Foundation BICYCLIC PEPTIDE INHIBITORS
CA3083600A1 (en) * 2017-12-04 2019-06-13 Heat Biologics, Inc. Production of cell-based vaccines
US11793884B2 (en) 2018-01-29 2023-10-24 Ohio State Innovation Foundation Cyclic peptidyl inhibitors of CAL-PDZ binding domain
US20210363192A1 (en) * 2018-04-27 2021-11-25 Spark Therapeutics, Inc. Engineered aav capsids with increased tropism and aav vectors comprising the engineered capsids and methods of making and using same
US11987647B2 (en) 2018-05-09 2024-05-21 Ohio State Innovation Foundation Cyclic cell-penetrating peptides with one or more hydrophobic residues
KR102167755B1 (ko) 2018-05-23 2020-10-19 주식회사 큐어바이오 단편화된 grs 폴리펩타이드, 이의 변이체 및 이들의 용도
EP3817776A4 (en) * 2018-07-02 2022-11-30 Ohio State Innovation Foundation POLYPEPTIDE CONJUGATES FOR INTRACELLULAR RELEASE OF NUCLEIC ACIDS
GB201812980D0 (en) 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
GB201812972D0 (en) 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
KR20210064254A (ko) * 2018-09-26 2021-06-02 가부시키가이샤 가네카 세포막 투과성 펩티드
WO2020115494A1 (en) * 2018-12-07 2020-06-11 Oxford University Innovation Limited Linkers
CN118079011A (zh) 2019-02-01 2024-05-28 利兰斯坦福初级大学董事会 用于将核酸递送至肺部的分解性细胞穿透复合物
US20220119450A1 (en) * 2019-02-04 2022-04-21 University Of Tartu Bi-specific extracellular matrix binding peptides and methods of use thereof
WO2020180938A1 (en) * 2019-03-05 2020-09-10 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for treating protein aggregation-associated diseases
WO2021004539A1 (zh) 2019-07-11 2021-01-14 厦门大学 用于胞内递送分子的复合物
KR20230096914A (ko) * 2019-07-22 2023-06-30 원스킨 인크. 항노화 효과를 갖는 폴리펩타이드 및 그의 용도
TWI889695B (zh) * 2019-08-02 2025-07-11 西班牙商Ｉｄｐ發現製藥公司 黑色素細胞調節胜肽
US12180255B2 (en) * 2019-11-22 2024-12-31 Alcamena Stem Cell Therapeutics, Llc Compositions and methods for derepressing RE1 silencing transcription factor target genes
WO2021113434A1 (en) 2019-12-03 2021-06-10 Rodan & Fields, Llc Peptides and compositions for inhibiting hair growth
KR20220121867A (ko) 2019-12-31 2022-09-01 시아먼 유니버시티 분자의 세포 내 전달을 위한 다량체화 전달 시스템
EP3906935A1 (en) 2020-05-06 2021-11-10 Sorbonne Universite Peptides for preventing or treating viral infections
CN113943778A (zh) * 2020-07-17 2022-01-18 通用电气医疗集团股份有限公司 用于核酸检测的分子探针及其制备方法和用途
MX2023007788A (es) 2021-01-24 2023-11-17 Michael David Forrest Inhibidores de la atp sintasa, usos cosmeticos y terapeuticos.
US20240182526A1 (en) * 2021-03-31 2024-06-06 University Of Southern California Compositions and methods for modulting inflammatory and degenerative disorder
JP2024513087A (ja) 2021-04-07 2024-03-21 アストラゼネカ・アクチエボラーグ 部位特異的改変のための組成物及び方法
CN115385987B (zh) * 2021-05-19 2024-08-02 中山大学 一种抗鱼类神经坏死病毒的穿膜肽及其应用
KR102504190B1 (ko) * 2021-06-03 2023-02-28 주식회사 레메디 화물분자 수송 도메인 rmmr1, 이의 변이체, 이를 포함하는 재조합 화물분자 및 이를 이용한 화물분자 수송 방법
KR102819567B1 (ko) * 2021-11-24 2025-06-13 주식회사 윙스타바이오 아밀로이드 전구체 단백질에 대한 저해 활성을 갖는 펩타이드 및 이의 용도
KR102793149B1 (ko) * 2021-11-24 2025-04-09 주식회사 윙스타바이오 아밀로이드 전구체 단백질에 대한 저해 활성을 갖는 펩타이드 및 이의 용도
CN114349846B (zh) * 2022-01-07 2023-12-15 天津市泌尿外科研究所 一种人精子膜蛋白or1d2特异性多肽与抗体的制备方法
CA3246201A1 (en) * 2022-03-23 2023-09-28 Council Of Scientific & Industrial Research PEPTIDE FOR TREATING DISORDERS BASED ON α-SYNUCLEIN AMYLOID
CN116444678B (zh) * 2022-10-18 2024-02-02 百葵锐(深圳)生物科技有限公司 一种具有真菌抗菌抑菌性能的新型多肽
JP2025540052A (ja) 2022-12-01 2025-12-11 イェール ユニバーシティー 細胞内ペイロード送達用刺激応答性トレースレス操作プラットフォーム
WO2025172421A1 (en) 2024-02-14 2025-08-21 Astrazeneca Ab Compositions and methods for treatment of huntington's disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0975370B9 (en) * 1997-05-21 2004-11-03 The Board Of Trustees Of The Leland Stanford Junior University Composition and method for enhancing transport across biological membranes
EP1037649B1 (en) * 1997-12-17 2009-09-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
EP1137664A2 (en) * 1998-12-10 2001-10-04 Washington University Protein transduction system and methods of use thereof
WO2001097830A1 (en) * 2000-06-22 2001-12-27 Mount Sinai School Of Medicine Modification of mdm2 activity
FR2810985B1 (fr) * 2000-07-03 2004-12-24 Synt Em Peptides lineaires amphipathiques et les compositions les contenant
AU8524901A (en) * 2000-08-25 2002-03-13 Aventis Pharma Inc Membrane penetrating peptides and uses thereof
IL154696A (en) * 2000-09-05 2008-11-03 Biosight Ltd Peptide conjugated anti-cancer prodrugs
FR2818981A1 (fr) * 2001-01-03 2002-07-05 Synt Em Peptides amphipathiques et leur utilisation pour le transfert de substances d'interet dans les cellules
AU2002240201A1 (en) * 2001-02-02 2002-08-19 Yale University Peptides for facilitating composite receptor expression and translocation of macromolecules
DE10390251D2 (de) * 2002-01-27 2004-12-23 Viromics Gmbh Trojanische Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung

Also Published As

Publication number Publication date
AU2003253125A1 (en) 2003-12-31
JP4503435B2 (ja) 2010-07-14
EP1516184B1 (en) 2007-08-01
EP1516184A2 (en) 2005-03-23
US20080234183A1 (en) 2008-09-25
ATE368853T1 (de) 2007-08-15
DE60315296D1 (de) 2007-09-13
DE60315296T2 (de) 2008-04-17
HK1078130A1 (en) 2006-03-03
JP2006514602A (ja) 2006-05-11
WO2003106491A3 (en) 2004-12-23
WO2003106491A2 (en) 2003-12-24
AU2003253125A8 (en) 2003-12-31

Similar Documents

Publication Publication Date Title
AU2003253125A8 (en) Cell penetrating peptides
IL178515A0 (en) Oligopeptides for reducing elevated blood urea concentration
WO2004089396A3 (en) Anti-fungal peptidomimetics
WO2003072599A3 (en) Novel chemokine binding peptides capable of modulating the biological activity of chemokines
WO2003085086A3 (en) Motif-grafted hybrid polypeptides and uses thereof
WO2003063760A3 (en) Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
WO2005119251A3 (en) Novel means and methods for the treatment of hearing loss and phantom hearing
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
IL172783A0 (en) Rasgap derived peptide for selectively killing cancer cells
AU2003240631A1 (en) A t cell subpopulation regulating gut immunity
ATE321782T1 (de) Membrantranslokierendes peptid als wirkstofftransportsystem
WO2007019865A3 (en) Therapy with cd4 binding peptides and radiation
PL1694697T3 (pl) Zlokalizowane na powierzchni polipeptydy campylobacter jejuni
TW200508249A (en) Antibodies for the cancer specific antigen
WO2005004894A3 (en) Methods for increasing cell and tissue viability
GB0207644D0 (en) Peptides and their use
MXPA06000661A (es) Npcili (npc3) y metodos de uso del mismo.
TR200100175T2 (tr) Otoimmün hastalıkların immünoterapisinde kullanılmak üzere yeni peptitler.
TW200517125A (en) Pharmaceutical composition for treatment of solid cancers
WO2005072766A3 (en) Peptides that bind to hsp90 proteins
EP1465911A4 (en) COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF DIABETES, INSULIN RESISTANCE AND DYSLIPIDEMIA
WO2010133806A3 (fr) Peptides marques et leur utilisation pour le dosage d'irap circulant
DE60327263D1 (de) Beta-strang-mimetika
MX2007014803A (es) Composiciones que penetran el nucleo celular.
WO2003099209A3 (en) Compositions and methods for screening and identifying anti-hcv agents